Do you want to read an article? Please log in or register.
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer
Breast Cancer
Related content
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
SPECIAL REPORT
Breast Cancer
Managing Side Effects in Breast Cancer Treatment
Breast Cancer
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial
JAMA Oncol
Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch M, Moroose R, Visco F, Hortobagyi GN, Slamon DJ, Fresco R, Zarate JP, Li Z, Waters S, Hurvitz SA
doi: 10.1001/jamaoncol.2025.3700
Breast Cancer
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial
Int J Cancer
Beierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Sütterlin MW, Ruebner M, Theuser AK, Hofmann NM, Böhm S, Almstedt K, Kellner S, Gass P, Lück HJ, Hein A, Schmatloch S, Kalder M, Uleer C, Juhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Huebner H, Goossens C, Brucker SY, Hack CC, Fehm TN, Fasching PA
doi: 10.1002/ijc.70037
COMMENTED
Breast Cancer
Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial
★ 2
Recommended and commented by
Dr Andreas Müller, Faculty Member
J Clin Oncol
Peccatori FA, Niman SM, Partridge AH, Ruggeri M, Colleoni M, Saura C, Shimizu C, Satersdal AB, Kroep JR, Gelmon K, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA Jr, International Breast Cancer Study Group and the POSITIVE Trial Collaborators
doi: 10.1200/JCO-24-02697
SPECIAL REPORT
Genitourinary Cancer
Insights from the EMBARK Trial: Identifying Eligible Patients for Optimized Outcomes
RECOMMENDED
Breast Cancer
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study
★ 1
Recommended by
Dr Andreas Müller, Faculty Member
J Clin Oncol
Valenza C, Zheng Y, Milano M, Trapani D, Giordano E, Guidi L, Berton Giachetti PPM, Boldrini L, Castellano G, Katrini J, Malagutti B, Antonarelli G, Conforti F, Pagan E, Bagnardi V, Kirkner GJ, Sangalli C, Dibble KE, Colleoni M, Regan MM, Munzone E, Curigliano G, Partridge AH
doi: 10.1200/JCO-25-01660
COMMENTED
Breast Cancer
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
★ 2
Recommended and commented by
Dr Andreas Müller, Faculty Member
J Clin Oncol
Gao HF, Ye GL, Lin Y, Huang Q, Dong J, Cao Y, Zhao YX, Chen QJ, Ma SH, Ouyang J, Ye JH, Yang HW, Zhang YQ, Zhang YC, Zhang GL, Li W, Zhang Y, Wu ZY, Lin YY, Zhu T, Zhang LL, Yang CQ, Yang M, Peng H, Chen B, Chen YT, Ji F, Cheng MY, Li JQ, Jiang Z, Wang K
doi: 10.1200/JCO-25-02176
Breast Cancer
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
Lancet Oncol
Beshr MS, Fahaid A, Shembesh RH, Valachis A, Lambertini M, Cortesi L, Alesawy AF, Abraheem A, Alsharedi M, Ali ME, Elkhanany A, Azim HA Jr, Velikova G, Elhadi M
doi: 10.1016/S1470-2045(26)00053-7